Intuitive SurgicalISRGEarnings & Financial Report
Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S.
ISRG Q4 2025 Key Financial Metrics
营收
$2.9B
毛利润
$1.9B
营业利润
$864.3M
净利润
$794.8M
毛利率
66.4%
营业利润率
30.2%
净利率
27.7%
同比增长
18.8%
EPS
$2.19
资金流向
Intuitive Surgical Q4 2025 Financial Summary
Intuitive Surgical reported revenue of $2.9B for Q4 2025, with a net profit of $794.8M (27.7% margin). Cost of goods sold was $961.9M, operating expenses totaled $1.0B.
Key Financial Metrics
| Total Revenue | $2.9B |
|---|---|
| Net Profit | $794.8M |
| Gross Margin | 66.4% |
| Operating Margin | 30.2% |
| Report Period | Q4 2025 |
Intuitive Surgical Annual Revenue by Year
Intuitive Surgical annual revenue history includes year-by-year totals (for example, 2025 revenue was $10.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $10.1B |
| 2024 | $8.4B |
| 2023 | $7.1B |
| 2022 | $6.2B |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $1.89B | $2.01B | $2.04B | $2.41B | $2.25B | $2.44B | $2.51B | $2.87B |
| 同比增长 | 11.5% | 14.5% | 16.9% | 25.2% | 19.2% | 21.4% | 22.9% | 18.8% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $15.83B | $16.65B | $17.74B | $18.74B | $19.22B | $20.16B | $19.35B | $20.46B |
| 总负债 | $1.78B | $1.85B | $2.07B | $2.21B | $2.01B | $2.21B | $2.31B | $2.52B |
| 股东权益 | $13.96B | $14.71B | $15.58B | $16.43B | $17.11B | $17.85B | $16.93B | $17.82B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $265.4M | $620.5M | $706.5M | $822.6M | $581.6M | $715.4M | $841.0M | $892.5M |
Other Health Care Companies
ABT
Abbott Laboratories
营收
$11.4B
净利润
$1.6B
BAX
Baxter International
营收
$3.0B
净利润
$-1.1B
BDX
Becton Dickinson
营收
$5.3B
净利润
$382.0M
BSX
Boston Scientific
营收
$5.3B
净利润
$670.0M
DXCM
Dexcom
营收
$1.3B
净利润
$267.3M
EW
Edwards Lifesciences
营收
$1.6B
净利润
$291.1M
GEHC
GE HealthCare
营收
$5.7B
净利润
$588.0M
HOLX
Hologic
营收
$1.0B
净利润
$179.1M
IDXX
Idexx Laboratories
营收
$1.1B
净利润
$274.6M
PODD
Insulet Corporation
营收
$783.7M
净利润
$101.6M